medigraphic.com

2000, Número 1

<< Anterior Siguiente >>

Enf Infec Microbiol 2000; 20 (1)


Comentarios en torno a la quimioprofilaxis antituberculosa en sujetos infectados por el VIH

García GML, Jiménez CME, Valdespino GJL

Idioma: Español
Referencias bibliográficas: 43
Paginas: 3-9
Archivo PDF: 36.95 Kb.


FRAGMENTO

En todo el mundo se ha observado el impacto del virus de la inmunodeficiencia humana (VIH) sobre la tuberculosis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Harries AD. Tuberculosis and human immunodeficiency virus infection in developing countries. Lancet 1990;335:387-90.

  2. Tapia R, Ruiz C, Ferreira E. Epidemiología de la tuberculosis en México. En: Sada E, Sifuentes J, editores. Tuberculosis. México: McGraw-Hill Interamericana Editores, 1995:761-88. (Ramiro HM, Saita OK, editores. Temas de Medicina Interna, vol. 3).

  3. Secretaría de Salud. Informe del Programa de Prevención y Control de la Tuberculosis, 1997.

  4. Valdespino JL, Velasco O, Escobar A. Enfermedades tropicales en México. Diagnóstico, tratamiento y distribución geográfica. México: Secretaría de Salud, 1994:215-25.

  5. Valdespino JL, García ML, Del Río A, Loo E, Magis C, Salcedo RA. Epidemiología del SIDA-VIH en México; de 1983 a marzo de 1995. Salud Publica Mex 1995;37:556-71.

  6. García ML, Valdespino JL, García-Sancho C, Salcedo R, Zacarías F, Sepúlveda J. Epidemiology of AIDS and tuberculosis. Bull Pan Am Health Organ 1995;29:37-59.

  7. Cano DC, Villarreal UC, Gómez CG, Ramírez CF, Becerra CG. La importancia de la tuberculosis en el síndrome de inmunodeficiencia adquirida. Gac Med Mex 1991;127:137- 41.

  8. Jessurum J, Ángeles-Ángeles A, Gasman N. Comparative demographic and autopsy findings in acquired immunodeficiency syndrome in two Mexican populations. J Acquir Immune Defic Syndr 1990;3:579-83.

  9. Mohar A, Romo J, Salido F, et al. The spectrum of clinical and pathological manifestations of AIDS in a consecutive series of autopsied patients in Mexico. AIDS 1992;6:467-73.

  10. García ML, Valdespino JL, Palacios M, Mayar ME, García Sancho C, Sepúlveda J. Tuberculosis y SIDA en México. Salud Publica Mex 1995;37:539-48.

  11. Bucher HC, Griffith LE, Guyatt GH, et al. Isonaizid prophylaxis for tuberculosis in HIV infection: A meta-analysis of randomized controlled trials. AIDS 1999;13:501-7.

  12. Wilkinson D, Squire S, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: Systematic review of randomized placebo controlled trials. BMJ 1998;317:625-9.

  13. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.

  14. Braun MM, Badi N, Ryder RW, et al. A retrospective cohort study of the risk of tuberculosis among women of childbearing age with HIV infection in Zaire. Am Rev Respir Dis 1991;143:501-4.

  15. Wadwahan D, Hira S, Mwansa N, Perine P. Preventive tuberculosis chemotherapy with isoniazid among persons infected with HIV -1. VIII International Conference on AIDS. June 1992, Amsterdam (abstract TuB0536).

  16. Valdespino JL, García ML, Daniels E, et al. Outcomes of the pilot study of TB chemoprophylaxis trials. IX International Conference on AIDS, Berlin, June 1993 (abstract PIOB07- 114).

  17. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda Case Western Reserve University Research Collaboration. N Engl J Med 1997;337:801-8.

  18. Turner MT. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans. N Engl J Med 1998;338:841-2.

  19. Desvarieux M. Questions about a placebo-controlled trial of preventive therapy for tuberculosis in HIV-infected Ugandans. N Engl J Med 1998;338:841 (Discussion, 842-3).

  20. Ponce de León S, Chiriboga C, editores. Guía para la atención médica de pacientes con infección por VIH/SIDA en consulta externa y hospitales. México: Secretaría de Salud, 1995:43-44.

  21. Secretaría de Salud. Norma Oficial Mexicana NOM-006-SSA2 1993, para la prevención y control de la tuberculosis en la atención primaria a la salud. Diario Oficial de la Federación, 26 de enero de 1995, págs. 20-29.

  22. Proyecto de modificación a la Norma Oficial Mexicana NOM-010-SSA2-1993. Para la prevención y control de la infección por virus de la inmunodeficiencia humana. Diario Oficial del 22 de septiembre de 1999.

  23. Centers for Disease Control. Screening for tuberculosis and tuberculosis infection in high risk populations: Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990;39 (RR-8):1-12.

  24. Centers for Disease Control. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR 1998;47 (RR-20):36-41.

  25. Tuberculosis preventive therapy in HIV-infected individuals: A joint statement of the International Union Against Tuberculosis and Lung Disease (IUATLD) and the Global Programme on AIDS and the Tuberculosis Programme of the World Health Organization (WHO). Tuber Lung Dis 1994;75:96-98.

  26. WHO Tuberculosis site. Policy statement on preventive therapy against tuberculosis in people living with HIV. http:/ /www.who.int/gtb/publications/TB_HIV_polstmnt/policy_ statement.html

  27. Small PM, Shaefer RW, Hopewell PC, et al. Exogenous reinfection with multidrug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993;328:1137-44.

  28. García-García ML, Palacios Martínez M, Ponce de León A, et al. The role of core groups in transmitting M. tuberculosis in a high prevalence community in Southern Mexico. Int J Tuberc Lung Dis 2000;4:12-17.

  29. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco: A population based study using conventional and molecular methods. N Engl J Med 1994;330:1708-9.

  30. Pan American Health Organization. Association between HIV and tuberculosis: Technical guide. Bull Pan Am Health Organ 1993;27:297-310.

  31. Huebner RE, Villarino ME, Snider DE Jr. Tuberculosis skin testing and the HIV epidemic. JAMA 1992;267:409-10.

  32. Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test energy in HIV-1-seropositive and -seronegative drug intravenous users. JAMA 1992;267:369-73.

  33. García-García ML, Valdespino JL, García SC, Mayar M, Palacios M, Balandrano S, et al. Underestimation of Mycobacterium tuberculosis infection in HIV-infected subjects using reactivity to tuberculin. Int J Epidemiol 1999. En prensa.

  34. Gordin FM, Chaisson RE, Matts JP, et al. An international, randomized trial of rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 1999. En prensa.

  35. Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with energy and human immunodeficiency virus infection who are the high risk for tuberculosis.

  36. Snider D, Simone P, Dooley S, Bloch A. Multidrug-resistant tuberculosis. Sci Am 1994;1:16-27.

  37. Sawert H, Girardi E, Antonucci G, Raviglione MC, Viale P, Ippolito G. Preventive therapy for tuberculosis in HIV-infected persons: Analysis of policy options based on tuberculin status and CD4+ cell count. Gruppo Italiano di Studio Tuberculosi e AIDS (GISTA). Arch Intern Med 1998;158: 2112-21.

  38. García-García ML, Valdespino-Gómez JL, García-Sancho C, et al. Underestimation of Mycobacterium tuberculosis infection in HIV subjects using reactivity to tuberculin and energy panel. Int J Epidemiol (en prensa).

  39. Valdespino-Gómez JL, García-García ML, García-Sancho, et al. Pulmonary tuberculosis among clients of HIV testing centers in Mexico. Int J Tuberc Lung Dis 1999;3 (suppl 1):196.

  40. De Cock KM, Grant A, Porter JD. Preventive therapy for tuberculosis in HIV-infected persons: International recommendations, research and practice. Lancet 1995;345: 833-6.

  41. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. New Engl J Med 1997;337:801-8.

  42. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis theraphy in HIV infection in Zambia. AIDS 1998;12:2447-57.

  43. Halsey NA, Coberly IS, Desormeaux J, et al. Randomized trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in VIH-1 infection. Lancet 1998;351:786-92.




2020     |     www.medigraphic.com